Effect of cetuximab in recurrent and refractory squamous cell carcinoma of the head and neck (SCCHN): a case report |
| |
| Authors: | Clorinda Schettino Maria Anna Bareschino Katia Monaco Michele Orditura Ferdinando De Vita Fortunato Ciardiello |
| |
| Institution: | (1) Division of Medical Oncology, Department of Clinical and Experimental Medicine and Surgery F. Magrassi and A. Lanzara, Second University of Naples School of Medicine, Via S. Panini 5, 80131 Naples, Italy |
| |
| Abstract: | The epidermal growth factor receptor (EGFR) is frequently overexpressed in squamous cell carcinoma of head and neck (SCCHN).
Different strategies to target the activated EGFR have reached the clinic. Cetuximab is a monoclonal antibody that selectively
binds to the extracellular domain of the EGFR on the tumor cell, thereby inhibiting receptor-associated tyrosine kinase activation.
Two randomized phase III clinical trials have recently demonstrated that cetuximab increases the activity of radiotherapy
in the treatment of locally advanced SCCHN and of platinum-based chemotherapy in the treatment of metastatic SCCHN. Here we
report the clinical case of a long-lasting complete response in a 57-year-old male, who was a current smoker and had a history
of alcohol abuse, affected by recurrent locally advanced SCCHN after failure of radiotherapy and of platinum-based chemotherapy. |
| |
| Keywords: | Head and neck cancer Cetuximab Monoclonal antibodies (MAbs) Epidermal growth factor receptor (EGFR) Antitumor activity Case report |
| 本文献已被 SpringerLink 等数据库收录！ |
